In various cancers, abnormal activation of the HGF/MET signaling pathway is caused by multiple mechanisms, including gene amplification, overexpression, the presence of different functional gain-of-function mutations, and abnormal secretion of HGF through autocrine or paracrine pathways [54]. The gene discussed is MET; the disease is cancer.